[go: up one dir, main page]

NO20083439L - Modulering av gen-utrykk ved hjelp av docosaheksaensyre - Google Patents

Modulering av gen-utrykk ved hjelp av docosaheksaensyre

Info

Publication number
NO20083439L
NO20083439L NO20083439A NO20083439A NO20083439L NO 20083439 L NO20083439 L NO 20083439L NO 20083439 A NO20083439 A NO 20083439A NO 20083439 A NO20083439 A NO 20083439A NO 20083439 L NO20083439 L NO 20083439L
Authority
NO
Norway
Prior art keywords
modulation
gene expression
docosahexaenoic acid
subject
dha
Prior art date
Application number
NO20083439A
Other languages
English (en)
Norwegian (no)
Inventor
Steven Charles Rumsey
Joshua C Anthony
Thomas J Brenna
Zeina Jouni
Kumar Sesha Durga Kothapalli
Deshanie Rai
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20083439L publication Critical patent/NO20083439L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20083439A 2006-02-28 2008-08-05 Modulering av gen-utrykk ved hjelp av docosaheksaensyre NO20083439L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77772406P 2006-02-28 2006-02-28
PCT/US2007/004451 WO2007100566A2 (fr) 2006-02-28 2007-02-21 Utilisation de dha et d'ara dans la préparation d'une composition permettant de réguler l'expression génique

Publications (1)

Publication Number Publication Date
NO20083439L true NO20083439L (no) 2008-11-28

Family

ID=38328537

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083439A NO20083439L (no) 2006-02-28 2008-08-05 Modulering av gen-utrykk ved hjelp av docosaheksaensyre

Country Status (11)

Country Link
US (1) US20090099259A1 (fr)
EP (1) EP1993530A2 (fr)
KR (1) KR20080106415A (fr)
CN (1) CN101431993A (fr)
BR (1) BRPI0708365A2 (fr)
CA (1) CA2645123A1 (fr)
MX (1) MX2008010881A (fr)
NO (1) NO20083439L (fr)
RU (1) RU2008138380A (fr)
TW (1) TW200810747A (fr)
WO (1) WO2007100566A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20100004334A1 (en) * 2008-07-01 2010-01-07 Mead Johnson Nutrition Company Nutritional Compositions Containing Punicalagins
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
US11360102B2 (en) 2015-09-23 2022-06-14 Boston Medical Center Corporation Biomarkers for the early detection of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1660065A (zh) * 1997-03-27 2005-08-31 布里斯托尔-迈尔斯斯奎布公司 二十二碳六烯酸和花生四烯酸促进不足月婴儿生长的用途
CN1160119C (zh) * 2001-02-27 2004-08-04 中国科学院上海生物化学研究所 Tob基因在哺乳动物中枢神经系统的功能及其应用
US8633246B2 (en) * 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids

Also Published As

Publication number Publication date
CN101431993A (zh) 2009-05-13
RU2008138380A (ru) 2010-04-10
US20090099259A1 (en) 2009-04-16
BRPI0708365A2 (pt) 2011-04-26
WO2007100566A3 (fr) 2008-10-09
TW200810747A (en) 2008-03-01
CA2645123A1 (fr) 2007-09-07
WO2007100566A2 (fr) 2007-09-07
EP1993530A2 (fr) 2008-11-26
KR20080106415A (ko) 2008-12-05
MX2008010881A (es) 2008-09-03

Similar Documents

Publication Publication Date Title
AR092479A1 (es) Plataforma de integracion de transgenes modificados por ingenieria genetica (etip) para reconocimiento de genes y apilamiento de rasgos
BR112012022570A2 (pt) moléculas de polinucleotídeo para regulação de gene em plantas.
BRPI0921758A2 (pt) bifidobacterium longum
AR074364A1 (es) Enzimas y metodo para producir acidos grasos omega -3
AR114027A2 (es) Construcciones de adn recombinante y métodos para modular la expresión de un gen diana
MX369077B (es) Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn.
WO2009070805A3 (fr) Gènes régulés par le mir-124 et cheminements servant de cibles pour une intervention thérapeutique
WO2008073920A3 (fr) Gènes et voies génétiques régulés par mir-21 utilisés en tant que cibles pour une intervention thérapeutique
MY176922A (en) Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
NO20083439L (no) Modulering av gen-utrykk ved hjelp av docosaheksaensyre
EP2384114A4 (fr) Nutraceutiques contenant des acides gras nitro
BRPI0510132A (pt) sìntese de ácidos graxos poliinsaturados de cadeia longa por células recombinantes
WO2009086156A3 (fr) Gènes et voies régulés par mir-10 servant de cibles dans le cadre d'une intervention thérapeutique
CO6351813A2 (es) "metodos y composiciones para mejorar la produccion de productos en microorganismos"
MX345116B (es) Modulacion de bcl11a para tratamiento de hemoglobinopatias.
AR092482A1 (es) Enriquecimiento de la clasificacion de las celulas activadas por fluorescencia (facs) para generar plantas
EP3822352A3 (fr) Procédés et compositions de modulation de l'expression de l'apolipoprotéine(a)
WO2008085797A3 (fr) Gènes et voies régulés par mir-16 utiles comme cibles pour intervention thérapeutique
AR085759A1 (es) Metodos para modificar la biosintesis de la lignina y mejorar la digestibilidad
PA8813901A1 (es) Paramixovirus oncolíticos atenuados que codifican citoquinas de aves
ATE528381T1 (de) Verwendung von carboxylsäureestern als duftstoff
EA201390592A1 (ru) Аллели 1-d-дезоксиксилулозо-5-фосфат синтазы, ответственные за усиленный биосинтез терпенов
MX2016008518A (es) Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo.
EA201400401A1 (ru) Биокомпозит для регенерации поврежденных тканей и органов, набор для изготовления биокомпозита и способ лечения
WO2008073921A3 (fr) Gènes et voies régulés par mir-126 comme cibles d'intervention thérapeutique

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application